Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase II is to study the efficacy and toxicity of carboplatin and
paclitaxel with pertuzumab and trastuzumab in HER2 positive and carboplatin and paclitaxel
with bevacizumab in HER2 negative in the neoadjuvant setting for the treatment of breast
cancer.